Clinical trials are experiments using human studies. Some patients enroll in clinical trials which allow them to gain access to cancer cancer A term used to describe diseases in which abnormal cells continually divide without normal regulation. Cancerous cells may invade surrounding tissues and may spread to other regions of the body via blood and the lymphatic system. treatments that are not FDA-approved. For MCC, there are active clinical trials using immune checkpoint inhibitors immune checkpoint inhibitors Immune checkpoint inhibitors (ICIs) are therapies that turns on the immune system by blocking an inhibitor (a 'checkpoint') that normally restrains the immune system. Such agents can sometimes cause the immune system to recognize and destroy a cancer. . Please visit our Immunotherapy page for more information on these agents. There is a need for more patients to enroll in clinical trials, as outlined by an MCC patient in the New York Times.
MCC patients with advanced stages that meet the clinical trial’s eligibility.
Patients that do not meet the clinical trial’s eligibility, or who are unable to travel to the site at which the trial is being performed.
Depending on the agent, there are many side effects ranging from fatigue to autoimmune responses.
Trials are very specific as to what can be used together with the agent being tested.
Please explore the National Institutes of Health’s website to learn more about active MCC clinical trials, their eligibility requirements, and location sites.
Typically, MCC clinical trials administer immune checkpoint inhibitors but also include chemotherapy, certain types of radiation, and combinations of therapies. Please explore the National Institutes of Health’s website to learn more about active MCC clinical trials, their eligibility, and location sites.
Every clinical trial have a different set of requirements, but can limit enrollment based on age, tumor size, extent of disease, past treatments and immune status.
The authoritative source on Merkel cell carcinoma.
January 5, 2018